Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 31,172 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 31,172 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $1.18, for a total transaction of $36,782.96. Following the transaction, the director owned 3,712,352 shares in the company, valued at approximately $4,380,575.36. The trade was a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $40,832.52.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total value of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $133,538.70.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock traded down $0.12 during trading hours on Thursday, hitting $0.98. 348,982 shares of the company’s stock traded hands, compared to its average volume of 498,843. The company has a fifty day simple moving average of $1.59 and a 200-day simple moving average of $1.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The stock has a market capitalization of $47.33 million, a price-to-earnings ratio of -0.60 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HOWL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. JMP Securities reduced their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday. Bank of America dropped their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Werewolf Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MPM Bioimpact LLC increased its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the last quarter. MPM Asset Management LLC lifted its position in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $28,000. Finally, Bank of America Corp DE increased its holdings in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.